BioNTech News

BioNTech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Oct 18 09:09 ET

BioNTech | 6-K: BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day

Oct 1 08:15 ET

BioNTech | 6-K: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

Sep 20 09:22 ET

BioNTech | 6-K: BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024

Sep 5 08:57 ET

BioNTech | 6-K: Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine

Aug 22 16:36 ET

BioNTech | 6-K: Lift of Partial Clinical Hold for BNT326/YL202

Aug 19 08:37 ET

BioNTech | 6-K: Pfizer and BioNtech Provide Update on mRNA-Based Combination Vaccine Program Against Influenza and Covid-19 in Individuals 18-64 Years of Age

Aug 16 06:58 ET

BioNTech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Aug 7 15:50 ET

BioNTech | 6-K: BioNTech SE Announced Positive Topline Data from the Ongoing Phase 2 Clinical Trial

Jul 30 09:10 ET

BioNTech | 6-K: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union

Jun 28 16:10 ET

BioNTech | 6-K: BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer

Jun 24 08:10 ET

BioNTech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jun 17 07:20 ET

BioNTech | 6-K: Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Jun 3 07:50 ET

BioNTech | 6-K: BioNTech and CEPI Expand Partnership to Strengthen Africa's mRNA Vaccine Ecosystem

May 30 15:42 ET

BioNTech | 6-K: BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024

May 21 16:41 ET

BioNTech | 6-K: Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

Apr 8 07:17 ET

BioNTech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Mar 25 15:44 ET

BioNTech | 6-K: BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

Mar 20 07:17 ET

BioNTech | 6-K: BioNTech to Present Clinical Data Updates For Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024

Mar 11 09:06 ET

BioNTech | 6-K: BioNTech Announces Planned Retirement of Sean Marett

Mar 7 08:44 ET